PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Avidity Biosciences, Inc. (RNA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US05370A1088

CUSIP

05370A108

Sector

Healthcare

IPO Date

Jun 28, 2013

Highlights

Market Cap

$3.81B

EPS (TTM)

-$2.88

Total Revenue (TTM)

$7.92M

Gross Profit (TTM)

$6.60M

EBITDA (TTM)

-$256.60M

Year Range

$13.73 - $56.00

Target Price

$67.91

Short %

15.45%

Short Ratio

11.42

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
RNA vs. NVDA RNA vs. STRO RNA vs. RXST
Popular comparisons:
RNA vs. NVDA RNA vs. STRO RNA vs. RXST

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Avidity Biosciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-40.00%-30.00%-20.00%-10.00%0.00%10.00%20.00%SeptemberOctoberNovemberDecember2025February
-29.14%
9.31%
RNA (Avidity Biosciences, Inc.)
Benchmark (^GSPC)

Returns By Period

Avidity Biosciences, Inc. had a return of 9.70% year-to-date (YTD) and 128.18% in the last 12 months.


RNA

YTD

9.70%

1M

10.30%

6M

-29.14%

1Y

128.18%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

4.46%

1M

2.46%

6M

9.31%

1Y

23.49%

5Y*

13.03%

10Y*

11.31%

*Annualized

Monthly Returns

The table below presents the monthly returns of RNA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202513.24%9.70%
202435.14%49.63%39.45%-5.45%11.31%52.08%11.58%-3.47%4.39%-7.99%1.82%-32.42%221.33%
20236.80%-0.00%-35.23%-19.22%-14.35%4.43%-14.25%-20.50%-15.61%-19.28%51.65%15.88%-59.22%
2022-30.08%2.05%8.90%-22.58%-2.59%4.31%12.11%20.44%-16.77%-12.55%-18.49%90.64%-6.65%
2021-10.34%5.46%-9.61%7.47%1.28%4.09%-21.85%18.28%7.84%-8.65%-0.76%6.45%-6.86%
2020-0.84%-0.25%2.16%-2.26%-12.15%21.07%-14.76%-10.46%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 89, RNA is among the top 11% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of RNA is 8989
Overall Rank
The Sharpe Ratio Rank of RNA is 9191
Sharpe Ratio Rank
The Sortino Ratio Rank of RNA is 8989
Sortino Ratio Rank
The Omega Ratio Rank of RNA is 8585
Omega Ratio Rank
The Calmar Ratio Rank of RNA is 9191
Calmar Ratio Rank
The Martin Ratio Rank of RNA is 8686
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Avidity Biosciences, Inc. (RNA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for RNA, currently valued at 1.90, compared to the broader market-2.000.002.001.901.74
The chart of Sortino ratio for RNA, currently valued at 2.74, compared to the broader market-4.00-2.000.002.004.006.002.742.35
The chart of Omega ratio for RNA, currently valued at 1.33, compared to the broader market0.501.001.502.001.331.32
The chart of Calmar ratio for RNA, currently valued at 2.22, compared to the broader market0.002.004.006.002.222.61
The chart of Martin ratio for RNA, currently valued at 7.04, compared to the broader market0.0010.0020.0030.007.0410.66
RNA
^GSPC

The current Avidity Biosciences, Inc. Sharpe ratio is 1.90. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Avidity Biosciences, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio2.004.006.008.0010.00SeptemberOctoberNovemberDecember2025February
1.90
1.74
RNA (Avidity Biosciences, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Avidity Biosciences, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%SeptemberOctoberNovemberDecember2025February
-39.24%
0
RNA (Avidity Biosciences, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Avidity Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Avidity Biosciences, Inc. was 86.45%, occurring on Oct 27, 2023. Recovery took 156 trading sessions.

The current Avidity Biosciences, Inc. drawdown is 39.24%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-86.45%Sep 15, 2020786Oct 27, 2023156Jun 12, 2024942
-48.48%Nov 14, 202440Jan 14, 2025
-25.87%Jun 23, 202019Jul 20, 202023Aug 20, 202042
-17.01%Oct 21, 202410Nov 1, 20248Nov 13, 202418
-15.95%Jul 29, 202429Sep 6, 202417Oct 1, 202446

Volatility

Volatility Chart

The current Avidity Biosciences, Inc. volatility is 14.12%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%SeptemberOctoberNovemberDecember2025February
14.12%
3.07%
RNA (Avidity Biosciences, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Avidity Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Avidity Biosciences, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab